Shares of Tilray Inc (NASDAQ:TLRY) have been given an average broker rating score of 2.33 (Buy) from the three brokers that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company.
Brokers have set a 12 month consensus price objective of $62.00 for the company and are anticipating that the company will post ($0.14) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Tilray an industry rank of 84 out of 255 based on the ratings given to related companies.
A number of equities analysts recently weighed in on TLRY shares. Roth Capital started coverage on shares of Tilray in a research report on Tuesday, August 14th. They issued a “buy” rating and a $35.00 price objective on the stock. Northland Securities lowered shares of Tilray from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 6th. Finally, Cowen started coverage on shares of Tilray in a research report on Monday, August 13th. They issued an “outperform” rating and a $34.00 price objective on the stock.
NASDAQ:TLRY opened at $140.00 on Friday. Tilray has a 1-year low of $20.10 and a 1-year high of $300.00.
Tilray (NASDAQ:TLRY) last posted its quarterly earnings data on Tuesday, August 28th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.08). The company had revenue of $9.70 million for the quarter, compared to analysts’ expectations of $9.01 million. The business’s revenue for the quarter was up 94.0% compared to the same quarter last year. Equities research analysts forecast that Tilray will post -0.45 EPS for the current year.
In related news, CRO Edward Wood Pastorius, Jr. bought 14,705 shares of the firm’s stock in a transaction on Monday, July 23rd. The shares were bought at an average cost of $17.00 per share, for a total transaction of $249,985.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Brendan Kennedy bought 14,706 shares of the firm’s stock in a transaction on Monday, July 23rd. The shares were bought at an average price of $17.00 per share, for a total transaction of $250,002.00. The disclosure for this purchase can be found here.
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc was incorporated in 2018 and is headquartered in Nanaimo, Canada.
Featured Article: Discover Your Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.